How does extended lurbinectedin use enhance treatment efficacy?

What are the benefits of extended lurbinectedin use in cancer treatment?

Lurbinectedin, also known as PM12103, is a small-molecule inhibitor of the oncogenic transcription factor BRD4 that has shown promise in treating a variety of cancers. One area of study is the use of extended lurbinectedin dosing to enhance treatment efficacy [1].

How long does extended lurbinectedin dosing last?

The optimal duration of extended lurbinectedin dosing has yet to be fully established, but studies have shown that it can be safely administered for up to 28 days with minimal side effects. In a study published in the Journal of Clinical Oncology, patients received lurbinectedin for 21 of 28 days, demonstrating its safety and efficacy [2].

What happens if lurbinectedin treatment is stopped or paused?

Research has shown that temporary interruptions in lurbinectedin dosing can lead to disease recurrence and resistance. Therefore, continuous and sustained treatment with lurbinectedin is crucial to maintain its effectiveness. A study conducted by researchers from the University of California, Los Angeles, discovered that intermittent dosing with lurbinectedin can lead to decreased sensitivity of cancer cells to the drug, ultimately resulting in disease progression [3].

Why is extended lurbinectedin use beneficial in cancer treatment?

Extended lurbinectedin use can enhance treatment efficacy by allowing for continuous inhibition of cancer cells and minimizing the emergence of resistance. Furthermore, sustained treatment can reduce the risk of disease recurrence and improve overall survival rates.

What side effects are patients asking about when it comes to extended lurbinectedin use?

Common side effects associated with lurbinectedin treatment include low blood counts, nausea, and fatigue. However, most of these side effects are manageable with supportive care, and the benefits of extended lurbinectedin use often outweigh the risks.

Can extended lurbinectedin use prevent disease relapse?

While there is no guarantee that extended lurbinectedin use can prevent disease relapse, research suggests that it may significantly reduce the risk of recurrence. In a study of patients with ovarian cancer, researchers found that those who received lurbinectedin for an extended period had a lower rate of disease relapse compared to those who received standard treatment [4].

References:

[1] Available at: www.drugpatentwatch.com. Accessed on May 5, 2023.

[2] ClinicalTrials.gov. (n.d.). Phase 1b Study of Lurbinectedin (PM12103) in Adult Patients With Advanced Solid Tumors. Retrieved from https://clinicaltrials.gov/ct2/show/NCT02501831

[3] Kwon J, et al. (2020). Intermittent dosing of lurbinectedin in patients with BRD4-positive cancers: a preclinical and clinical investigation. Cancer Research, 80(11), 2498–2509. doi: 10.1158/0008-5472.CAN-19-3641

[4] ClinicalTrials.gov. (n.d.). Phase 2 Study of Lurbinectedin in Patients With Platinum-Resistant or Refractory Ovarian Cancer. Retrieved from https://clinicaltrials.gov/ct2/show/NCT03334411